Athira Pharma, Inc. — Director's Dealing 2021

Jun 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2021-05-18

Reporting Person: MILESON GLENNA (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Stock	A	1554	$14.45	Acquired	83519	Direct
2021-06-10	Common Stock	M	6305	$1.35	Acquired	89824	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-10	Stock Option (Right to Buy)	$1.35	M	6305	Disposed	2028-12-17	Common Stock (6305)	Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of October 2, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c).

F2: The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began October 2, 2020.

F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the initial public offering price from the issuer's initial public offering.

F4: The shares subject to the option fully vested on January 1, 2021.